Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A1 | P68400 | 3/20 | 0.67 |
| ▸ | VCP | P55072 | 1/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 9/20 | 0.66 |
| ▸ | MEN1 | O00255 | 8/20 | 0.66 |
| ▸ | MAPT | P10636 | 6/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.66 |
| ▸ | GAA | P10253 | 1/20 | 0.66 |
| ▸ | RAB9A | P51151 | 1/20 | 0.66 |
| ▸ | HTT | P42858 | 3/20 | 0.65 |
| ▸ | MAOA | P21397 | 3/20 | 0.64 |
| ▸ | MAOB | P27338 | 3/20 | 0.64 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.62 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.62 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.62 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.62 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.62 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.62 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.62 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.62 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL7146574 | 0.99 | KMT2A (0.68) | CSNK2A1VCPKMT2AMEN1MAPT | |
| SCHEMBL24340403 | 0.89 | KMT2A (0.69) | CSNK2A1VCPKMT2AMEN1MAPT | |
| SCHEMBL8684018 | 0.88 | CSNK2A1 (0.67) | CSNK2A1VCPKMT2AMEN1MAPT | |
| SCHEMBL10919656 | 0.87 | KMT2A (0.67) | CSNK2A1VCPKMT2AMEN1MAPT | |
| SCHEMBL10922701 | 0.86 | KMT2A (0.72) | CSNK2A1VCPKMT2AMEN1MAPT | |
| SCHEMBL10808167 | 0.86 | BAZ1A (0.79) | CSNK2A1VCPKMT2AMEN1MAPT | |
| SCHEMBL10962764 | 0.85 | KMT2A (0.74) | CSNK2A1VCPKMT2AMEN1MAPT | |
| SCHEMBL3613551 | 0.85 | RAB9A (0.70) | KMT2AMEN1MAPTALDH1A1GAA | |
| SCHEMBL15689083 | 0.84 | RAB9A (0.73) | CSNK2A1VCPKMT2AMEN1MAPT | |
| SCHEMBL30294205 | 0.84 | CSNK2A1 (0.71) | CSNK2A1VCPKMT2AMEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100298340-A1 | Thiazol-Guanidine Derivatives Useful As A (Beta)-Related Pathologies | ASTRAZENECA AB (SE) | 2010-11-25 | — | — | US | claimed |
| CN-101466692-A | Thiazol-guanidine derivatives useful as a (beta) - related pathologies | ASTRAZENECA AB (SE) | 2009-06-24 | — | — | CN | claimed |
| EP-2010508-A1 | THIAZOL-GUANIDINE DERIVATIVES USEFUL AS A (BETA)- RELATED PATHOLOGIES | AstraZeneca AB (SE) | 2009-01-07 | — | — | EP | claimed |
| WO-2007120096-A1 | THIAZOL-GUANIDINE DERIVATIVES USEFUL AS A (BETA)- RELATED PATHOLOGIES | ASTRAZENECA AB (SE) | 2007-10-25 | — | — | WO | claimed |
| EP-4638427-A1 | AMIDINOUREA DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER | Université Côte d'Azur (FR) | 2025-10-29 | — | — | EP | disclosed |
| WO-2024133857-A1 | AMIDINOUREA DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER | UNIVERSITE COTE D'AZUR (FR) | 2024-06-27 | — | — | WO | disclosed |
| CN-111825633-B | Method for synthesizing 2-guanidyl thiazole compounds by one-pot method | 西华大学 | 2023-11-17 | — | — | CN | disclosed |
| US-11440906-B2 | Biguanide derivatives and their rearrangement products for use in the treatment of cancer | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2022-09-13 | — | — | US | disclosed |
| EP-3728211-A1 | BIGUANIDE DERIVATIVES AND THEIR REARRANGEMENT PRODUCTS FOR USE IN THE TREATMENT OF CANCER | Centre National de la Recherche Scientifique (FR) | 2020-10-28 | — | — | EP | disclosed |
| CN-111836803-A | Compounds and their use in the treatment of cancer | 国家科学研究中心 | 2020-10-27 | — | — | CN | disclosed |
| US-20200308156-A1 | BIGUANIDE DERIVATIVES AND THEIR REARRANGEMENT PRODUCTS FOR USE IN THE TREATMENT OF CANCER | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2020-10-01 | — | — | US | disclosed |
| US-20100298340-A1 | Thiazol-Guanidine Derivatives Useful As A (Beta)-Related Pathologies | ASTRAZENECA AB (SE) | 2010-11-25 | — | — | US | disclosed |
| CN-101466692-A | Thiazol-guanidine derivatives useful as a (beta) - related pathologies | ASTRAZENECA AB (SE) | 2009-06-24 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298340-A1 | Thiazol-Guanidine Derivatives Useful As A (Beta)-Related Pathologies | GRN, MAPT, GUCY1B1 | CSNK2A1 1563/4885VCP 1390/4885KMT2A 4116/4885 |
| US-20200308156-A1 | BIGUANIDE DERIVATIVES AND THEIR REARRANGEMENT PRODUCTS FOR USE IN THE TREATMENT OF CANCER | BCR, G6PD, BRAF | CSNK2A1 1210/4885VCP 2644/4885KMT2A 3118/4885 |
| US-11440906-B2 | Biguanide derivatives and their rearrangement products for use in the treatment of cancer | BCR, G6PD, BRAF | CSNK2A1 1210/4885VCP 2644/4885KMT2A 3118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.